JP2007502817A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502817A5
JP2007502817A5 JP2006523866A JP2006523866A JP2007502817A5 JP 2007502817 A5 JP2007502817 A5 JP 2007502817A5 JP 2006523866 A JP2006523866 A JP 2006523866A JP 2006523866 A JP2006523866 A JP 2006523866A JP 2007502817 A5 JP2007502817 A5 JP 2007502817A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
pharmaceutical salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006523866A
Other languages
English (en)
Other versions
JP2007502817A (ja
JP4754487B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/024387 external-priority patent/WO2005019212A1/en
Publication of JP2007502817A publication Critical patent/JP2007502817A/ja
Publication of JP2007502817A5 publication Critical patent/JP2007502817A5/ja
Application granted granted Critical
Publication of JP4754487B2 publication Critical patent/JP4754487B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

本発明は式I:
Figure 2007502817
I;
[式中、
1およびR2はそれぞれ独立してH、OH、シアノ、C1−C6アルキル、C1−C6アルコキシ、CF3、ハロまたはNR44'であり、
3はH、C1−C6アルキルであり、
Xは、適宜C1−C4アルキルで置換される五員芳香族ヘテロ環であり、ここで前記ヘテロ環はN、SおよびOから選択された少なくとも2つまたは3つのヘテロ原子を含み、ここで少なくともひとつのヘテロ原子はNでなくてはならず、
YはS、CR5=NまたはN=CR5であり、
nは2、3、4、5、6または7であり、
4はH、COR6、SO27またはC1−C6アルキルであり、
4'はHまたはC1−C6アルキルであり、
5はHであるか、またはXとの結合を形成し、
6はHまたはC1−C6アルキルであり、
7はHまたはC1−C6アルキルである]
で示される化合物、またはその医薬的な塩に関する。

Claims (5)

  1. 式I:
    Figure 2007502817
    I;
    [式中、
    1およびR2はそれぞれ独立してH、OH、シアノ、C1−C6アルキル、C1−C6アルコキシ、CF3、ハロまたはNR44'であり;
    3はH、C1−C6アルキルであり;
    Xは、適宜C1−C4アルキルで置換されていてもよい5員芳香族ヘテロ環であり;ここに、該ヘテロ環はN、SおよびOから選択された少なくとも2または3のヘテロ原子を含み、ここに、少なくとも一つのヘテロ原子はNでなくてはならず;
    YはS、CR5=NまたはN=CR5であり;
    nは2、3、4、5、6または7であり;
    4はH、COR6、SO27またはC1−C6アルキルであり;
    4'はHまたはC1−C6アルキルであり;
    5はHであるか、またはXとの結合を形成し;
    6はHまたはC1−C6アルキルであり;
    7はHまたはC1−C6アルキルであるが;但し、式Iの化合物は式:
    Figure 2007502817
    ではない]
    で示される化合物、またはその医薬的な塩。
  2. 3がHである、請求項1記載の化合物。
  3. Xが式:
    Figure 2007502817
    であり;R3がHであり、(CH2nCO23部分が2の位置にて付加している、請求項1または2記載の化合物、またはその医薬的な塩。
  4. a)請求項2もしくは3記載の化合物またはその医薬的な塩;およびb)GLP−1化合物を含む、医薬組成物。
  5. a)請求項2もしくは3記載の化合物またはその医薬的な塩;およびb)MC4アゴニストペプチドを含む、医薬組成物。
JP2006523866A 2003-08-20 2004-08-18 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤 Expired - Fee Related JP4754487B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49653703P 2003-08-20 2003-08-20
US60/496,537 2003-08-20
PCT/US2004/024387 WO2005019212A1 (en) 2003-08-20 2004-08-18 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide

Publications (3)

Publication Number Publication Date
JP2007502817A JP2007502817A (ja) 2007-02-15
JP2007502817A5 true JP2007502817A5 (ja) 2007-05-31
JP4754487B2 JP4754487B2 (ja) 2011-08-24

Family

ID=34216017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006523866A Expired - Fee Related JP4754487B2 (ja) 2003-08-20 2004-08-18 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
JP2011104435A Pending JP2011207886A (ja) 2003-08-20 2011-05-09 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011104435A Pending JP2011207886A (ja) 2003-08-20 2011-05-09 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤

Country Status (12)

Country Link
US (3) US20070293423A1 (ja)
EP (1) EP1658285B1 (ja)
JP (2) JP4754487B2 (ja)
CN (1) CN100398536C (ja)
AT (1) ATE361294T1 (ja)
AU (1) AU2004267044B8 (ja)
BR (1) BRPI0413676B8 (ja)
CA (1) CA2530983C (ja)
DE (1) DE602004006279T2 (ja)
ES (1) ES2286679T3 (ja)
MX (1) MXPA06001916A (ja)
WO (1) WO2005019212A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2286825B1 (en) 2005-07-08 2016-09-28 Ipsen Pharma Melanocortin receptor ligands
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
CA2662853C (en) * 2006-08-31 2016-07-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
JP5628796B2 (ja) 2008-06-09 2014-11-19 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド
EP2440227B1 (en) 2009-06-08 2017-10-18 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US10357348B2 (en) * 2013-08-19 2019-07-23 Warren Matthew Leevy Fluid manifold
US20160244860A1 (en) * 2015-02-20 2016-08-25 Cytec Industries Inc. Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN105017136A (zh) * 2015-07-24 2015-11-04 陈吉美 一种2-溴-3-甲氧基吡啶的制备方法
EA201991839A1 (ru) 2017-02-08 2020-02-17 Байер Акциенгезельшафт Новые производные триазолтиона
US20200017467A1 (en) 2017-02-08 2020-01-16 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
EP3580218A1 (en) 2017-02-08 2019-12-18 Bayer CropScience Aktiengesellschaft Novel triazole derivatives
JP2020507579A (ja) 2017-02-10 2020-03-12 バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft 1−(フェノキシ−ピリジニル)−2−(1,2,4−トリアゾール−1−イル)−エタノール誘導体を含む有害微生物を制御するための組成物
WO2020020816A1 (en) 2018-07-26 2020-01-30 Bayer Aktiengesellschaft Novel triazole derivatives
CN111793038B (zh) * 2019-04-08 2022-08-12 新发药业有限公司 一种取代噁唑化合物的环保制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US595503A (en) * 1897-12-14 Cross-clevis
US2423709A (en) * 1947-07-08 X-aryl thiazole
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
NL8720442A (nl) * 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU3461697A (en) * 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
PT1093819E (pt) * 1997-02-07 2006-09-29 Emisphere Tech Inc Compostos e composicoes para fornecimento de agentes activos
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
NZ512581A (en) 1999-01-08 2002-12-20 Univ Virginia Commonwealth Polymeric delivery agents comprising a polymer conjugated to a modified amino acid and derivatives thereof
ES2251976T3 (es) * 1999-02-11 2006-05-16 Emisphere Technologies, Inc. Compuestos y composiciones de oxadiazol para aportar agentes activos.
CA2364849A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE288415T1 (de) 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU2622301A (en) 1999-11-05 2001-05-14 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
DE60038183T2 (de) 1999-12-16 2009-02-19 Emisphere Technologies, Inc. Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
WO2001051454A1 (en) 2000-01-13 2001-07-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2001273153B2 (en) 2000-06-29 2005-11-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SK1872003A3 (en) * 2000-08-23 2003-07-01 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
ATE368653T1 (de) * 2000-08-23 2007-08-15 Lilly Co Eli Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
JP4148672B2 (ja) * 2000-11-17 2008-09-10 武田薬品工業株式会社 イソオキサゾール誘導体
US7022725B2 (en) * 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
IL156561A0 (en) 2000-12-21 2004-01-04 Glaxo Group Ltd Macrolide antibiotics
WO2002064607A1 (fr) * 2001-02-14 2002-08-22 Meiji Seika Kaisha, Ltd. Nouveaux derives de macrolides a 16 elements modifies en 12 et 13
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
AU2002305720A1 (en) * 2001-05-30 2002-12-09 Huening, Tracy, T. Piperazine pentanamide hiv protease inhibitors
KR100957516B1 (ko) * 2001-08-15 2010-05-14 이코스 코포레이션 2h-프탈라진-1-온 및 이것의 사용 방법
US6969057B2 (en) 2001-10-30 2005-11-29 Illinois Tool Works Inc. Method and apparatus for adjusting and positioning air caps
WO2003057215A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Accelerateur de production/secretion de facteur neurotrophique
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
JP2004277397A (ja) * 2002-05-24 2004-10-07 Takeda Chem Ind Ltd 1,2−アゾール誘導体
CA2487315A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
AU2004251616A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide

Similar Documents

Publication Publication Date Title
JP2007502817A5 (ja)
RU2374241C2 (ru) N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы
JP2007519721A5 (ja)
JP2005510563A5 (ja)
JP2004536811A5 (ja)
JP2005507872A5 (ja)
JP2005507918A5 (ja)
JP2002543183A5 (ja)
JP2006526031A5 (ja)
JP2009501177A5 (ja)
JP2009501178A5 (ja)
JP2011522789A5 (ja)
JP2005053931A5 (ja)
JP2009519243A5 (ja)
JP2007522220A5 (ja)
JP2005511547A5 (ja)
JP2005112864A5 (ja)
JP2002501049A5 (ja)
JP2010523476A5 (ja)
JP2005539088A5 (ja)
JP2007510619A5 (ja)
JP2007532575A5 (ja)
JP2005538089A5 (ja)
JP2007518798A5 (ja)
JP2007500222A5 (ja)